Revolution Medicines (NASDAQ:RVMD) Shares Up 5.3% – Here’s What Happened

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report)’s share price shot up 5.3% during mid-day trading on Friday. The company traded as high as $166.31 and last traded at $167.8150. 617,670 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 2,800,772 shares. The stock had previously closed at $159.43.

Analyst Upgrades and Downgrades

RVMD has been the topic of several recent analyst reports. Bank of America dropped their price target on Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a research report on Friday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Revolution Medicines in a research note on Thursday, October 15th. Truist Financial restated a “buy” rating and issued a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a research report on Thursday, November 5th. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Revolution Medicines in a research note on Thursday, August 27th. Finally, TD Cowen boosted their target price on Revolution Medicines from $250.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $262.75.

Get Our Latest Stock Report on Revolution Medicines

Revolution Medicines Price Performance

The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. The company has a market capitalization of $34.89 billion, a price-to-earnings ratio of -17.65 and a beta of 1.44. The company has a fifty day simple moving average of $190.87 and a two-hundred day simple moving average of $160.71.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping the consensus estimate of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same quarter last year, the company earned ($1.61) EPS. As a group, research analysts anticipate that Revolution Medicines, Inc. will post -7.41 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Mark A. Goldsmith sold 13,988 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the completion of the sale, the insider owned 253,342 shares of the company’s stock, valued at $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elizabeth M. Anderson sold 10,143 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total value of $1,958,004.72. Following the transaction, the director directly owned 4,333 shares of the company’s stock, valued at $836,442.32. This trade represents a 70.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 273,901 shares of company stock valued at $53,970,418 in the last quarter. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. acquired a new position in Revolution Medicines in the second quarter valued at $551,843,000. Assenagon Asset Management S.A. grew its position in shares of Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after purchasing an additional 1,980,699 shares in the last quarter. Winslow Capital Management LLC bought a new stake in shares of Revolution Medicines during the 3rd quarter valued at about $260,191,000. Bank of America Corp DE bought a new position in Revolution Medicines during the second quarter valued at approximately $184,267,000. Finally, Deutsche Bank AG bought a new position in shares of Revolution Medicines in the second quarter worth approximately $166,308,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

See Also

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.